Skip to main content
Log in

A Phase II Study of Irofulven (MGI 114) in Patients with Stage IV Melanoma

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Sixteen patients with stage IV melanoma,who were heavily pretreated, received11 mg/m2/day of intravenous Irofulvenfor five consecutive days every 28 days.There were no objective tumor responses,although one patient exhibited stabledisease after 4 cycles. The most commontoxicities were grade 1/2 nausea, vomiting,fatigue, anemia, and thrombocytopenia. Onepatient required a dose reduction for anelevated creatinine while another patientrequired cessation of treatment because ofacute ataxia that may have been related toIrofulven. Based upon these data, Irofulvendoes not demonstrate significant antitumoractivity to warrant further investigationin advanced melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Houghton AN, Legha S, Bajorin DF: Chemotherapy for metastatic melanoma. In: Balch CM, Houghton AN, Milton GW, et al (eds) Cutaneous Melanoma. JB. Lippincott CO, Philadelphia, 1992, p. 499

    Google Scholar 

  2. Hill GJ Jr., Krementz ET, Hill HZ: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group Protocols 7130, 7131, and 7131A). Cancer 53(6): 1299–305, 1984

    Google Scholar 

  3. Legha SS: Current therapy for malignant melanoma. Semin Oncol 16(1, Suppl 1): 34–44, 1989

    Google Scholar 

  4. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR: Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11(10): 1969–1977, 1993

    Google Scholar 

  5. Demchak PA, Mier JW, Robert NJ, O'Brien K, Gould JA, Atkins MB: Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 9(10): 1821–1830, 1991

    Google Scholar 

  6. Flaherty LE, Robinson W, Redman BG, Gonzalez R, Martino S, Kraut M, Valdivieso M, Rudolph AR: A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 71(11): 3520–3525, 1993

    Google Scholar 

  7. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier J, Sparano JA, Fischer RI: Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12(8): 1553–1560, 1994

    Google Scholar 

  8. Kelner MJ, McMorris TC, Estes L: Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells: Unusually high sensitivity in ERCC2 and ERCC3 DNA helicase-deficient mutants compared to other chemotherapeutic agents. Biochem Pharmacol 48: 403–409, 1994

    Google Scholar 

  9. Izbicka E, Davidson K, Von Hoff DD: MGI-114 antiproliferative effects against human tumor cell lines with different p53 and p21waf expression. Anticancer Res 19: 1299–1308, 1999

    Google Scholar 

  10. Kelner MJ, McMorris TC, Taetle R: Preclinical evaluation of illudins as anticancer agents: Basis for selective cytotoxicity. J Natl Cancer Inst 82: 1562–1565, 1990

    Google Scholar 

  11. Kelner MJ, McMorris TC, Taetle R: In vitro and in vivo studies on the anticancer activity of dehydroilludin M. Anticancer Res 15: 873–878, 1995

    Google Scholar 

  12. Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK: Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol 18(24): 4086–4097, 2000

    Google Scholar 

  13. Sato Y, Kashimoto S, MacDonald JR, Nakona K: In vivo activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF) in various human tumor xenograft models including several lung and gastric tumors. Eur J Canc 37(11): 1419–28, 2001

    Google Scholar 

  14. Simon R: Clinical Trials. In: DeVita VT, Hellman S, and Rosenberg SA (eds) Cancer: Principles and Practice of Oncology 6th edition.: Lippincott, Williams, and Wilkins Publishers, Philadelphia, 2001, pp 521–538

    Google Scholar 

  15. Casper ES, Bajorin D: Phase II trial of carboplatin in patients with advanced melanoma. Investigational New Drugs 8(2): 187–90, 1990

    Google Scholar 

  16. Verma S, Quirt IC, Eisenhauer EA, Iscos NA, Young VJ, Bodurtha AJ, Davidson J: A phase II trial of weekly edatrexate (10-EDAM) in metastatic melanoma: A National Cancer Institute of Canada Clinical Trials Group Study. Ann Oncol 4(3): 254–5, 1993

    Google Scholar 

  17. Sessa C, Aamdal S, Wolff I, Eppelbaum R, Smyth JF, Sulkes A, ten Bokkel Huinin KW, Vermorken J, Wanders J, Franklin H: Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trial Group. Ann Oncol 5(5): 471–2, 1994

    Google Scholar 

  18. Aamdal S, Bruntsch U, Kerger J, Verweij J, ten Bokkel Huinin KW, Wanders J, Rastogi R, Franklin HR, Kaye SB: Zeniplatin in advanced malignant melanoma and renal cancer: Phase II studies with unexpected nephrotoxicity. Cancer Chemother Pharmacol 40(5): 439–43, 1997

    Google Scholar 

  19. Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS: Phase II trial of doxil for patients with metastatic melanoma refractory to front line therapy. Oncol Rep 6(5): 1097–9, 1999

    Google Scholar 

  20. Gonzalez R, Ebbinghaus S, Henthorn TK, Miller D, Kraft AS: Treatment of patients with metastatic melanoma with bryostatin-a phase II study. Melanoma Res 9(6): 599–606, 1999

    Google Scholar 

  21. Weitman S, Barrera H, Moore R, Gonzalez C, Marty J, Hilsenbeck S, MacDonald JR, Waters SJ, Von Hoff DD: MGI-114: augmentation of antitumor activity when combined with topetecan. J Ped Hematol Oncol 22(4): 306–14, 2000

    Google Scholar 

  22. Hammond LA, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S: Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topetecan or paclitaxel in the MV522 lung carcinoma xenograft model. Eur J Canc 36(18): 2430–6, 2000

    Google Scholar 

  23. Kelner MJ, McMorris TC, Estes L, Samson KM, Trani NA, MacDonald JR: Anti-leukemic action of the novel agent MGI-114 (HMAF) and synergistic action with topetecan. Leukemia 14(1): 136–41, 2000

    Google Scholar 

  24. Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold S, MacDonald JR, Rowinksky EK, Von Hoff DD, Weitman S: Enhanced activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res 59(5): 1049–53, 1999

    Google Scholar 

  25. Kraut EH, Walker MJ, Staubus A, Gochnour D, Balcerzak SP: Phase II trial of topotecan in malignant melanoma. Cancer Invest 15(4): 318–20, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pierson, A.S., Gibbs, P., Richards, J. et al. A Phase II Study of Irofulven (MGI 114) in Patients with Stage IV Melanoma. Invest New Drugs 20, 357–362 (2002). https://doi.org/10.1023/A:1016261918256

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016261918256

Navigation